Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Response Biomedical and BioTheranostics

Premium

Response Biomedical said this week that its board of directors has appointed Jeffrey Purvin to be CEO and a director, and that Peter Thompson has stepped down from the interim CEO position that he has held for nearly one year. Thompson will remain executive chairman of the company's board of directors.

Purvin has 30 years of experience marketing consumer and medical products and is a member of the board of directors, audit committee, and finance committee and chair of the compensation committee at Cardica.


BioTheranostics said this week that it has added Brad Smith, Brian Armstrong, and Francois Valencony to its board of directors, and has hired Mary Jo Mullen and Isaac Bright to its senior management, naming Mullen chief commercial officer and Bright vice president of corporate development.

Smith is a former vice chairman of Laboratory Corporation of America; Armstrong is chief financial officer for BioMérieux; and Valencony is managing director of Merieux Development.

Mullen formerly held senior sales management positions at LabCorp. Bright joins the company from QuantaLife and held corporate and business development leadership posts at Medtronic and an investment banking position at CIBC World Markets.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.